High-Throughput Drug Screening on Borrelia garinii and Borrelia afzelii Identified Hypocrellin A as an Active Drug Candidate Against Borrelia Species

Author:

Li Tingting1,Xin Yuxian1,Liu Dongxia1,Sun Jingrong1,Li Jingwei1,Zhang Ying,Feng Jie

Affiliation:

1. School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

Abstract

Abstract Lyme disease (LD) is a tick-transmitted infection caused by Borrelia burgdorferi sensu lato species, which include B. burgdorferi, Borrelia afzelii and Borrelia garinii. The majority of patients with early LD can be cured by the standard treatment, yet some still suffer from posttreatment LD syndrome. The presence of Borrelia persisters has been proposed as a contributing factor, because they cannot be completely eradicated by the currently used antibiotics for LD. Finding new pharmaceuticals targeting Borrelia persisters is crucial for developing more effective treatments. Here, we first confirmed the existence of persisters in B. garinii and B. afzelii cultures and then conducted a high-throughput screening of a custom drug library against persister-rich stationary-phase B. garinii and B. afzelii cultures. Among 2427 compounds screened, hypocrellin A (HA), anthracycline class of drugs and topical antibiotics along with some other natural compounds were identified to have strong potential for killing persisters of B. garinii and B. afzelii. HA was the most active anti-Borrelia compound, capable of eradicating stationary-phase Borrelia persisters, in particular when combined with doxycycline and/or ceftriaxone. Liposoluble antioxidant vitamin E was found to antagonize the activity of HA, indicating HA’s target is the cell membrane where HA triggers the generation of reactive oxygen species in the presence of light. HA was found to have distinct bactericidal activity against Borrelia species but had poor or no activity against gram-positive and gram-negative bacteria. Identification of the abovementioned drug candidates may help develop more effective therapies for LD.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Microbiology (medical),Infectious Diseases,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3